Error in Key Points and Table 1

No authors listed

Published Erratum

No authors listed. JAMA Oncol. 2025.

. 2025 Jun 1;11(6):675.

doi: 10.1001/jamaoncol.2025.0928.

No abstract available

Erratum for

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.
Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, Kachnic LA, Gillin MT, Hong TS, Craig TD, Williams TM, Hosni A, Chen E, Noonan AM, Koay EJ, Sinha R, Lock MI, Ohri N, Dorth JA, Delouya G, Swaminath A, Moughan J, Crane CH. Dawson LA, et al. JAMA Oncol. 2025 Feb 1;11(2):136-144. doi: 10.1001/jamaoncol.2024.5403. JAMA Oncol. 2025. PMID: 39699905 Clinical Trial.

1. Dawson LA, Winter KA, Knox JJ, et al. Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG Oncology/RTOG 1112 phase 3 randomized clinical trial. JAMA Oncol. 2025;11(2):136-144. doi: 10.1001/jamaoncol.2024.5403 - DOI - PMC - PubMed